Syros Pharmaceuticals
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
35 Cambridgepark Dr Fl 4, Cambridge, Mas...Phone Number
(617) 744-1340Website
www.syros.comRevenue
<$5 MillionStock Symbol
SYRSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. Its lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge,...Explore more
Syros Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syros Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Syros Pharmaceuticals has new funding data
Syros Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Syros Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Syros Pharmaceuticals recently announced quarterly report
Check out if Syros Pharmaceuticals is spiking on competitors!
Check if Syros Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Syros Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Syros Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Syros Pharmaceuticals
Find more new buyers
Compare Similar Companies to Syros Pharmaceuticals
Compare insights from companies similar to Syros Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Syros Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Syros Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Syros Pharmaceuticals.
Syros Pharmaceuticals financials insights
Gather financial insights about Syros Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$30M
2014
Series B
$53M
2016
Series C
$40M
Stock Offering
$57.5M
2017
Share Placement
$35M
2018
Stock Offering
$42.9M
Share Placement
$1.4M
2019
Stock Offering
$70M
2020
Debt
$60M
Stock Offering
$90.5M
Syros Pharmaceuticals Tech Stack
A closer look at the technologies used by Syros Pharmaceuticals
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Syros Pharmaceuticals News & Media
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in ... - Le Lézard
Syros Pharmaceuticals , a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with...Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is SyrSyros Reports Third Quarter 2024 Financial Results and Provides a Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. “It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic syndSyros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (interna
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Syros Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. Its lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and... Read More
